Clinical Trial Update: Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluated whether silymarin can reduce cisplatin-induced nephrotoxicity in patients with upper gastrointestinal adenocarcinoma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Silymarin (silymarin)

Snippet

Sponsor: Tehran University of Medical Sciences | Conditions: Upper GI Cancer, Cisplatin Adverse Reaction | Phase 2, Phase 3 | Status: COMPLETED